Jay Bradner

7PUBLICATIONS
78CO-AUTHORS
Molecular targetsBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Reaction engineering (excl. nuclear reactions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 29, 2022
A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer.

Helen Tanton, Tomasz Sewastianik, Hyuk-Soo Seo

|Feb 06, 2021
Targeting oncoproteins with a positive selection assay for protein degraders.

Vidyasagar Koduri, Leslie Duplaquet, Benjamin L Lampson

|Feb 01, 2021
Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer.

Catríona M Dowling, Kate E R Hollinshead, Alessandra Di Grande

|Aug 25, 2020
Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo.

Dawei Zhou, Tsuyoshi Hayashi, Maxime Jean

|Dec 02, 2017
Synthetic transcription elongation factors license transcription across repressive chromatin.

Graham S Erwin, Matthew P Grieshop, Asfa Ali

|Jul 14, 2017
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.

Abhishek A Chakraborty, Eijiro Nakamura, Jun Qi

Pageof 2

Frequent Collaborators

3 joint publications

Jun Qi

2 joint publications

William G Kaelin

1 joint publications

Salomon Manier

1 joint publications

Daisy Huynh